The Swiss Cancer Community has reimagined the challenges of Swiss cancer care and formulated seven main goals for 2032. In collaboration with over 400 experts from 150 organizations and departments within Swiss cancer care, 27 workshops and four networking events (2022-2023) were held to identify priority goals for specific areas and describe the necessary measures.

1. Primary Prevention: By 2032, cancer-specific gaps in primary prevention will be identified and addressed (Focus Area 1).
2. Early Detection: By 2032, 90% of the target groups for recommended cancer screenings will have access to systematic, standardized early detection programs (Focus Area 2)
3. Equitable Access: By 2032, cancer patients will have rapid and equitable access to evidence-based and innovative therapies (Focus Area 3).
4. Cancer Survivorship: By 2032, effective support services for people living with and after cancer will be available in all cantons (Focus Area 4).
5. Healthcare Professionals. By 2032, there will be a sufficient number of medical professionals in Swiss cancer care, and this will be sustainably secured (Transversal Theme 1).  
6. Clinical Research. By 2032, cancer patients will have access to appropriate clinical trials as part of their treatment (Transversal Theme 2).
7. Data. By 2032, cancer-specific patient data will be collected, transmitted, and utilized in a standardized manner in terms of content, structure, and technology (Transversal Theme 3).
   

   ---

    

The SAKK is particularly committed to Transversal Themes 5, 6, and 7

Addressing the Oncology-Specific Shortage of Skilled Professionals

For the past 10 years, we have been nurturing young oncologists through the Young Oncology Academy. In this mentoring program, mentees benefit from the knowledge of experienced researchers, gain access to the network, and enhance their skills.

Enhancing Patient Care through Clinical Research

Clinical cancer research is at the core of our work. Every day, we strive to improve therapies, enhance the quality of life for those affected, and increase their chances of recovery. Our 20 research groups conduct cross-center clinical trials across Switzerland, covering all types of cancer and medical specialties.

Through the active involvement of the SAKK Patient Advisory Board, we make a significant contribution to the development of clinical trials that address the needs of patients and their loved ones and are designed to be patient-friendly. Members of the Patient Advisory Board are involved early in the discussions within the groups and the development of the studies, bringing their valuable experiences to the table.

Efficient Collection, Transmission, and Utilization of Cancer-Specific Patient Data

Recently, SAKK entered a partnership with the Swiss Personalized Health Network (SPHN) and its nationwide BioMedIT network. This significant step enables standardized and efficient data exchange between Swiss healthcare institutions and supports the goals of the Master Plan 2025. This initiative advances research in personalized medicine to sustainably improve healthcare.

Further information click here (german).